Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* Diagnosis of alopecia areata with \>50% scalp involvement, alopecia totalis, or alopecia universalis~* Hair loss present for at least 6 months~* No treatment for alopecia areata in past 2 months~* No evidence of hair regrowth~* Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication~* Fluent in spoken and written English~Exclusion Criteria:~* Age \<18 years old~* Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study~* Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)~* Patients known to be HIV or hepatitis B or C positive~* Patients with positive tuberculin skin test or positive QuantiFERON TB test~* Patients with leukopenia or anemia~* Patients with renal or hepatic impairment~* Patients with peptic ulcer disease~* Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors~* Women of childbearing potential who are unable or unwilling to use birth control while taking the medication~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): Participants will receive tofacitinib for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).